"Earlier this year, AbbVie won an intense bidding war for Pharmacyclics, paying $21 billion for the company and the right to split sales of its potential blockbuster blood-cancer drug Imbruvica with Johnson & Johnson. AstraZeneca may have just done AbbVie one better."
"Acerta reported promising results from mid-phase trials of its drug last week, suggesting it may be even more effective than Imbruvica in treating relapsed chronic lymphocytic leukemia (CLL), with fewer side effects. The drug showed a 95 percent response rate (meaning the percentage of patients whose cancer shrinks or vanishes), compared to 58 percent for Imbruvica. AstraZeneca predicts peak sales of about $5 billion, compared to the $10 billion AbbVie projects for Imbruvica. "